Perspective Articles

Theranostics: Are We at a Turning Point for Nuclear Medicine?

Main Article Content

Francisco Norton Brandão
Miguel Barbosa
Lutetium, Precision Medicine, Theranostic Nanomedicine, Nuclear Medicine, Prostatic Neoplasms, Radiopharmaceuticals

Article Details

How to Cite
Perspective Articles


Sartor, O. PSMAfore Phase 3 Trial of [177Lu]Lu-PSMA-617 in Taxane-Naive Patients with Metastatic Castration Resistant Prostate Cancer. Unpublished data: trial results presented in 2023 European Society for Medical Oncology annual meeting. 2023-09-16. pp. 385(12):1091-1103.

Mileva EG, de Vries T, Guiot Z, Wimana A, Deleu C, Schröder C, et al. Molecular imaging predicts response absence to T-DM1 in advanced HER2-positive breast cancer: final results from a prospective phase II ZEPHIR trial [Online] [accessed 10/11/2023] Available at:

Kerrmann K, Schwaiger M, Lewis J, Solomon S, McNeill B, Baumann M, et al. Radioteranostics: a roadmap for future development. Lancet Oncol. 2020;21:e146-56. doi: 10.1016/S1470-2045(19)30821-6.

Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091-103. doi: 10.1056/NEJMoa2107322.

Hofman S, Emmett L, Sandhu S, Iravani A, Joshua A, Goh J, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797-804. doi: 10.1016/S0140-6736(21)00237-3.

European Medicines Agency. Resumo das Características do Medicamento - Pluvicto. [accessed 10/11/2023] Available at: